article thumbnail

Wave sees RNA editing validation in early trial results

BioPharma Drive: Drug Pricing

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

RNA 358
article thumbnail

From Impossible to Inevitable: Transforming Undruggable Targets

DrugBank

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. Laying down a new track for RNA processing, Remix launched with $81 million in financing. Nuance Pharma . Pear Therapeutics.

RNA 52
article thumbnail

HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel

The Pharma Data

Since announcing the Early Access Program on December 8, response from top academic institutions and leading pharmaceutical companies around the world has exceeded our expectations,” said Byron Lawson, Chief Commercial Officer.

article thumbnail

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be enforced successfully in a variety of European healthcare settings

The Pharma Data

1), (2), (3) Interim findings were presented at the 18th European AIDS Conference (EACS 2021) being held 27-30 October. Utmost people living with HIV on the trial agreed or fully agreed that long- acting cabotegravir and rilpivirine was largely respectable, applicable and doable to apply ( mean scores of4.6,4.6,4.6

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies.

article thumbnail

ViiV Healthcare Announces Analysis Showing no Antiretroviral Therapy Interruptions Due to COVID-19 Across its Clinical Development Programme for Investigational, Long-Acting Cabotegravir and Rilpivirine

The Pharma Data

The long-acting regimen of cabotegravir and rilpivirine is an investigational regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).